Rigel Pharmaceuticals, Inc.

RIGL

US7665596034

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 17:40:59 20/05/2024 BST			5-day change	1st Jan Change
0.958 ^USD	+0.80%		-3.28%	-34.48%

05-07	Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	MT

Rigel Pharmaceuticals, Inc. Announces Resignation of Anne-Marie Duliege, Executive Vice President and Chief Medical Officer, Effective August 31, 2019

May 16, 2019 at 12:30 pm

Rigel Pharmaceuticals, Inc. announced the resignation of Anne-Marie Duliege, Executive Vice President and Chief Medical Officer, effective August 31, 2019.

Latest news about Rigel Pharmaceuticals, Inc.

Transcript : Rigel Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Revenue $29.5M, vs. Street Est of $31.5M	05-07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rigel Pharmaceuticals, Inc. Enters into Amendment No. 4 to that Certain Credit and Security Agreement	04-12	CI
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer	03-12	CI
Citigroup Adjusts Rigel Pharmaceuticals' Price Target to $4 From $3, Maintains Buy Rating	03-07	MT
Transcript : Rigel Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q4 Revenue $35.8M, vs. Street Est of $33.4M	03-05	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
B. Riley Lifts Rigel Pharmaceuticals' PT to $1.75 From $1.25 After Announced Purchase of US Rights to Gavreto From Blueprint Medicines; Keeps Neutral Rating	02-26	MT
Rigel Pharmaceuticals Seeks Acquisitions	01-11	CI
Transcript : Rigel Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 12:00 PM	01-11
Rigel Pharmaceuticals Enters Collaboration to Study Possible Treatment for Brain Tumors; Shares Rise	01-04	MT
Rigel Pharmaceuticals, Inc. Announces Collaboration with Connect to Conduct a Phase 2 Trial of Olutasidenib in Glioma	01-04	CI
Rigel Pharmaceuticals, MD Anderson Partner for Research on New Rezlidhia Indications	12-08	MT
Rigel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center Announce Strategic Alliance to Advance REZLIDHIA®? (Olutasidenib) in AML and Other Cancers	12-08	CI
B. Riley Trims Rigel Pharmaceuticals' PT to $1.25 From $1.75, Lowers Peak Sales Estimate for Rezlidhia; Maintains Neutral Rating	11-09	MT
Transcript : Rigel Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q3 Revenue $28.1M, vs. Street Est of $27.2M	11-07	MT
Rigel Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition	11-02	CI
Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial	11/10/23	CI
Athersys Names Jane Wasman as Board Chair	02/10/23	MT
Transcript : Rigel Pharmaceuticals, Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-27-2023 03:35 PM	27/09/23

Chart Rigel Pharmaceuticals, Inc.

Duration

Period

More charts

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Sector

Biotechnology & Medical Research

Calendar

22/05/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Rigel Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.9504 USD

Average target price

4.533 USD

Spread / Average Target

+376.99%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RIGEL PHARMACEUTICALS, INC.	-34.48%	167M
VERTEX PHARMACEUTICALS INCORPORATED	+9.72%	115B
REGENERON PHARMACEUTICALS, INC.	+11.68%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-13.30%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.27%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+6.50%	14.32B
SAREPTA THERAPEUTICS, INC.	+33.98%	12.42B

Bio Therapeutic Drugs